rhC1INH: a new drug for the treatment of attacks in hereditary angioedema caused by C1-inhibitor deficiency

References

• Varga L, Farkas H. Treatment of type I and II hereditary angioedema with Rhucin, a recombinant human C1 inhibitor. Expert Rev. Clin. Immunol.4(6), 653–661 (2008).
   PubMed Web of Science ®Google Scholar
• Donaldson VH, Evans RR. A biochemical abnormality in herediatry angioneurotic edema: absence of serum inhibitor of C´ 1-esterase. Am. J. Med.35, 37–44 (1963).
   PubMed Web of Science ®Google Scholar
• Pappalardo E, Caccia S, Suffritti C, Tordai A, Zingale LC, Cicardi M. Mutation screening of C1 inhibitor gene in 108 unrelated families with hereditary angioedema: functional and structural correlates. Mol. Immunol.45(13), 3536–3544 (2008).
   PubMed Web of Science ®Google Scholar
• Bork K. Diagnosis and treatment of hereditary angioedema with normal C1 inhibitor. Allergy Asthma Clin. Immunol.6(1), 15 (2010).
   PubMedGoogle Scholar
• Cicardi M, Zanichelli A. Acquired angioedema. Allergy Asthma Clin. Immunol.6(1), 14 (2010).
   PubMedGoogle Scholar
• Davis AE, 3rd. Hereditary angioedema: a current state-of-the-art review, III: mechanisms of hereditary angioedema. Ann. Allergy Asthma Immunol.100(1 Suppl. 2), S7–S12 (2008).
   PubMed Web of Science ®Google Scholar
• Gurewich V, Pannell R. Recombinant human C1-inhibitor prevents non-specific proteolysis by mutant pro-urokinase during optimal fibrinolysis. Thromb. Haemost.102(2), 279–286 (2009).
   PubMed Web of Science ®Google Scholar
• Kaplan AP, Ghebrehiwet B. The plasma bradykinin-forming pathways and its interrelationships with complement. Mol. Immunol.47(13), 2161–2169 (2010).
   PubMed Web of Science ®Google Scholar
• Bork K, Hardt J, Schicketanz KH, Ressel N. Clinical studies of sudden upper airway obstruction in patients with hereditary angioedema due to C1 esterase inhibitor deficiency. Arch. Intern. Med.163(10), 1229–1235 (2003).
   PubMed Web of Science ®Google Scholar
• Agostoni A, Cicardi M. Hereditary and acquired C1-inhibitor deficiency: biological and clinical characteristics in 235 patients. Medicine (Baltimore)71(4), 206–215 (1992).
   PubMed Web of Science ®Google Scholar
• Frank MM, Gelfand JA, Atkinson JP. Hereditary angioedema: the clinical syndrome and its management. Ann. Intern. Med.84(5), 580–593 (1976).
   PubMed Web of Science ®Google Scholar
• Agostoni A, Aygoren-Pursun E, Binkley KE et al. Hereditary and acquired angioedema: problems and progress: proceedings of the third C1 esterase inhibitor deficiency workshop and beyond. J. Allergy Clin. Immunol.114(3 Suppl.), S51–S131 (2004).
   PubMed Web of Science ®Google Scholar
• Bas M, Hoffmann TK, Kojda G, Bier H. [ACE-inhibitor induced angioedema]. Laryngorhinootologie86(11), 804–808, quiz 9–13 (2007).
   PubMed Web of Science ®Google Scholar
• Bork K, Fischer B, Dewald G. Recurrent episodes of skin angioedema and severe attacks of abdominal pain induced by oral contraceptives or hormone replacement therapy. Am. J. Med.114(4), 294–298 (2003).
   PubMed Web of Science ®Google Scholar
• Bork K, Meng G, Staubach P, Hardt J. Hereditary angioedema: new findings concerning symptoms, affected organs, and course. Am. J. Med.119(3), 267–274 (2006).
   PubMed Web of Science ®Google Scholar
• Farkas H, Harmat G, Fay A, Fekete B, Karadi I, Visy B, Varga L. Erythema marginatum preceding an acute oedematous attack of hereditary angioneurotic oedema. Acta Derm. Venereol.81(5), 376–377 (2001).
   PubMed Web of Science ®Google Scholar
• Kemp JG, Craig TJ. Variability of prodromal signs and symptoms associated with hereditary angioedema attacks: a literature review. Allergy Asthma Proc.30(5), 493–499 (2009).
   PubMed Web of Science ®Google Scholar
• Farkas H, Harmat G, Kaposi PN et al. Ultrasonography in the diagnosis and monitoring of ascites in acute abdominal attacks of hereditary angioneurotic oedema. Eur. J. Gastroenterol. Hepatol.13(10), 1225–1230 (2001).
   PubMed Web of Science ®Google Scholar
• Bork K, Staubach P, Eckardt AJ, Hardt J. Symptoms, course, and complications of abdominal attacks in hereditary angioedema due to C1 inhibitor deficiency. Am. J. Gastroenterol.101(3), 619–627 (2006).
   PubMed Web of Science ®Google Scholar
• Neri S, Ierna D, Sfogliano L. Unusual manifestations of hereditary angioedema. Eur. J. Emerg. Med.7(2), 111–112 (2000).
   PubMedGoogle Scholar
• Farkas H. Management of upper airway edema caused by hereditary angioedema. Allergy Asthma Clin. Immunol.6(1), 19 (2010).
   PubMedGoogle Scholar
• Bowen T, Cicardi M, Farkas H et al. 2010 International consensus algorithm for the diagnosis, therapy and management of hereditary angioedema. Allergy Asthma Clin. Immunol.6(1), 24 (2010).
   PubMedGoogle Scholar
• Cicardi M, Zanichelli A. Angioedema due to C1 inhibitor deficiency in 2010. Intern. Emerg. Med.5(6), 481–486 (2010).
   PubMed Web of Science ®Google Scholar
• Zuraw BL. HAE therapies: past present and future. Allergy Asthma Clin. Immunol.6(1), 23 (2010).
   PubMedGoogle Scholar
• Longhurst HJ, Farkas H, Craig T et al. HAE international home therapy consensus document. Allergy Asthma Clin. Immunol.6(1), 22 (2010).
   PubMedGoogle Scholar
• Gompels MM, Lock RJ, Abinun M et al. C1 inhibitor deficiency: consensus document. Clin. Exp. Immunol.139(3), 379–394 (2005).
   PubMed Web of Science ®Google Scholar
• Bowen T, Cicardi M, Bork K et al. Hereditary angiodema: a current state-of-the-art review, VII: Canadian Hungarian 2007 International Consensus Algorithm for the Diagnosis, Therapy, and Management of Hereditary Angioedema. Ann. Allergy Asthma Immunol.100(1 Suppl. 2), S30–S40 (2008).
   Web of Science ®Google Scholar
• Farkas H, Jakab L, Temesszentandrasi G et al. Hereditary angioedema: a decade of human C1-inhibitor concentrate therapy. J. Allergy Clin. Immunol.120(4), 941–947 (2007).
   PubMed Web of Science ®Google Scholar
• Craig TJ, Levy RJ, Wasserman RL et al. Efficacy of human C1 esterase inhibitor concentrate compared with placebo in acute hereditary angioedema attacks. J. Allergy Clin. Immunol.124(4), 801–808 (2009).
   PubMed Web of Science ®Google Scholar
• Craig TJ, Wasserman RL, Levy RJ et al. Prospective study of rapid relief provided by c1 esterase inhibitor in emergency treatment of acute laryngeal attacks in hereditary angioedema. J. Clin. Immunol.30(6), 823–829 (2010).
   PubMed Web of Science ®Google Scholar
• Zuraw B, Cicardi M, Levy RJ et al. Recombinant human C1-inhibitor for the treatment of acute angioedema attacks in patients with hereditary angioedema. J. Allergy Clin. Immunol.126(4), 821–827, e14 (2010).
   PubMed Web of Science ®Google Scholar
• Bernstein JA, Qazi M. Ecallantide: its pharmacology, pharmacokinetics, clinical efficacy and tolerability. Expert Rev. Clin. Immunol.6(1), 29–39 (2010).
   PubMed Web of Science ®Google Scholar
• Cicardi M, Banerji A, Bracho F et al. Icatibant, a new bradykinin-receptor antagonist, in hereditary angioedema. N. Engl. J. Med.363(6), 532–541 (2010).
   PubMed Web of Science ®Google Scholar
• Longhurst HJ. Management of acute attacks of hereditary angioedema: potential role of icatibant. Vasc. Health Risk Manag.6, 795–802 (2010).
   PubMedGoogle Scholar
• Prematta M, Gibbs JG, Pratt EL, Stoughton TR, Craig TJ. Fresh frozen plasma for the treatment of hereditary angioedema. Ann. Allergy Asthma Immunol.98(4), 383–388 (2007).
   PubMed Web of Science ®Google Scholar
• Birgerson L. Tranexamic acid in the treatment of hereditary angioedema. Am. J. Med.91(1), 102 (1991).
   PubMed Web of Science ®Google Scholar
• Fust G, Farkas H, Csuka D, Varga L, Bork K. Long-term efficacy of danazol treatment in hereditary angioedema. Eur. J. Clin. Invest.41(3), 256–262 (2011).
   PubMed Web of Science ®Google Scholar
• Bork K, Bygum A, Hardt J. Benefits and risks of danazol in hereditary angioedema: a long-term survey of 118 patients. Ann. Allergy Asthma Immunol.100(2), 153–161 (2008).
   PubMed Web of Science ®Google Scholar
• Farkas H, Czaller I, Csuka D et al. Theeffect of long-term danazol prophylaxis on liver function in hereditary angioedema – a longitudinal study. Eur. J. Clin. Pharmacol.66(4), 419–426 (2010).
   PubMed Web of Science ®Google Scholar
• Zuraw BL, Busse PJ, White M et al. Nanofiltered C1 inhibitor concentrate for treatment of hereditary angioedema. N. Engl. J. Med.363(6), 513–522 (2010).
   PubMed Web of Science ®Google Scholar
• Cocchio C, Marzella N. Cinryze, a human plasma-derived c1 esterase inhibitor for prophylaxis of hereditary angioedema. Pharm. Therap.34(6), 293–328 (2009).
   Google Scholar
• Bork K, Hardt J. Hereditary angioedema: long-term treatment with one or more injections of C1 inhibitor concentrate per week. Int. Arch. Allergy Immunol.154(1), 81–88 (2010).
   PubMed Web of Science ®Google Scholar
• Saito T, Namura O, Honma T, Hayashi J. Supplementation of C1-esterase inhibitor concentrates for a patient suffering from hereditary angioedema undergoing complex open-heart surgery. Eur. J. Cardiothorac. Surg.37(4), 975–977 (2010).
   PubMed Web of Science ®Google Scholar
• Farkas H, Gyeney L, Gidofalvy E, Fust G, Varga L. The efficacy of short-term danazol prophylaxis in hereditary angioedema patients undergoing maxillofacial and dental procedures. J. Oral Maxillofac. Surg.57(4), 404–408 (1999).
   PubMed Web of Science ®Google Scholar
• Van Sickels NJ, Hunsaker RB, JE Van Sickels. Hereditary angioedema: treatment, management, and precautions in patients presenting for dental care. Oral Surg. Oral Med. Oral Pathol. Oral Radiol. Endod.109(2), 168–172 (2010).
   PubMed Web of Science ®Google Scholar
• Bernstein JA, Coleman S, Bonnin AJ. Successful C1 inhibitor short-term prophylaxis during redo mitral valve replacement in a patient with hereditary angioedema. J. Cardiothorac. Surg.5, 86 (2010).
   PubMedGoogle Scholar
• Spyridonidou A, Iatrou C, Alexoudis A, Vogiatzaki T, Polychronidis A, Simopoulos C. Peri-operative management of a patient with hereditary angioedema undergoing laparoscopic cholecystectomy. Anaesthesia65(1), 74–77 (2010).
   PubMed Web of Science ®Google Scholar
• Farkas H, Varga L, Szeplaki G, Visy B, Harmat G, Bowen T. Management of hereditary angioedema in pediatric patients. Pediatrics120(3), e713–e22 (2007).
   PubMed Web of Science ®Google Scholar
• Farkas H. Pediatric hereditary angioedema due to C1-inhibitor deficiency. Allergy Asthma Clin. Immunol.6(1), 18 (2010).
   PubMedGoogle Scholar
• Davis AE 3rd, Lu F, Mejia P. C1 inhibitor, a multi-functional serine protease inhibitor. Thromb. Haemost.104(5), 886–893 (2010).
   PubMed Web of Science ®Google Scholar
• Carter PE, Dunbar B, Fothergill JE. Genomic and cDNA cloning of the human C1 inhibitor. Intron-exon junctions and comparison with other serpins. Eur. J. Biochem.173(1), 163–169 (1988).
   PubMedGoogle Scholar
• Perkins S. Three-dimensional structure and molecular modelling of C1-inhibitor. Behring Inst. Mitt.93, 63–80 (1993).
   Google Scholar
• Eldering E, Nuijens JH, Hack CE. Expression of functional human C1 inhibitor in COS cells. J. Biol. Chem.263(24), 11776–11779 (1988).
   PubMed Web of Science ®Google Scholar
• Eldering E, Huijbregts CC, Lubbers YT, Longstaff C, Hack CE. Characterization of recombinant C1 inhibitor P1 variants. J. Biol. Chem.267(10), 7013–7020 (1992).
   PubMed Web of Science ®Google Scholar
• Lamark T, Ingebrigtsen M, Bjornstad C, Melkko T, Mollnes TE, Nielsen EW. Expression of active human C1 inhibitor serpin domain in Escherichia coli. Protein Expr. Purif.22(2), 349–358 (2001).
   PubMed Web of Science ®Google Scholar
• Wolff MW, Zhang F, Roberg JJ et al. Expression of C1 esterase inhibitor by the baculovirus expression vector system: preparation, purification, and characterization. Protein Expr. Purif.22(3), 414–421 (2001).
   PubMed Web of Science ®Google Scholar
• Longhurst H. Rhucin, a recombinant C1 inhibitor for the treatment of hereditary angioedema and cerebral ischemia. Curr. Opin. Investig. Drugs9(3), 310–323 (2008).
   PubMed Web of Science ®Google Scholar
• Koles K, van Berkel PH, Pieper FR et al. N- and O-glycans of recombinant human C1 inhibitor expressed in the milk of transgenic rabbits. Glycobiology14(1), 51–64 (2004).
   PubMed Web of Science ®Google Scholar
• Koles K, van Berkel PH, Mannesse ML, Zoetemelk R, Vliegenthart JF, Kamerling JP. Influence of lactation parameters on the N-glycosylation of recombinant human C1 inhibitor isolated from the milk of transgenic rabbits. Glycobiology14(11), 979–986 (2004).
   PubMed Web of Science ®Google Scholar
• van Doorn MB, Burggraaf J, T van Dam et al. A Phase I study of recombinant human C1 inhibitor in asymptomatic patients with hereditary angioedema. J. Allergy Clin. Immunol.116(4), 876–883 (2005).
   PubMed Web of Science ®Google Scholar
• Relan A, Hack CE, Haase G, Pijpstra R. Mechanistic implications from the treatment of acute angioedema attacks in hereditary angioedema (HAE) with recombinant human C1 inhibitor (rhC1INH) (poster). Presented at: XXIII International Complement Workshop. NY, USA, 1–5 August 2010.
   Google Scholar
• Choi G, Soeters MR, Farkas H et al. Recombinant human C1-inhibitor in the treatment of acute angioedema attacks. Transfusion47(6), 1028–1032 (2007).
   PubMed Web of Science ®Google Scholar
• Relan A, Haase G, Hack E, Nuijens J, Giannetti B, Pijpstra R. Dose justification for recombinant human C1INH for the treatment of acute angioedema attacks in patients with hereditary angioedema. Allergy65(s92), S1186 (2010).
   Google Scholar
• Moldovan D, Levy RJ, Visscher S, Relan A, Nuijens JH, Hack CE. Interim results from ongoing open-label studies with recombinant C1 inhibitor (Rhucin; rC1INH) for treatment of patients with acute attacks of hereditary angioedema (oral presentation). Presented at: 6th C1 Inhibitor Deficiency Workshop 2009. Budapest, Hungary, 22–24 May 2009.
   Google Scholar
• Kusuma A, Relan A, Haase G et al. Clinical value for the treatment with rhC1INH of patients with hereditary angioedema (HAE) suffering from an acute peripheral angioedema attack. Allergy65(S92), 1182 (2010).
   PubMed Web of Science ®Google Scholar
• Varga L, Szeplaki G, Visy B et al. C1-inhibitor (C1-INH) autoantibodies in hereditary angioedema. Strong correlation with the severity of disease in C1-INH concentrate naive patients. Mol. Immunol.44(6), 1454–1460 (2007).
   PubMed Web of Science ®Google Scholar
• Baboeram A, Relan A, Hack E et al. Immunogenicity assessment of recombinant human C1 Inhibitor (rhC1INH). Allergy65(S92), 1184 (2010).
   Google Scholar
• Pijpstra R, Hack E, Baboeram A et al. IgE against rabbit allergens and the therapeutic use of recombinant human C1 inhibitor. Allergy65(S92), S1185 (2010).
   Google Scholar
• Tillou X, Poirier N, Le Bas-Bernardet S et al. Recombinant human C1-inhibitor prevents acute antibody-mediated rejection in alloimmunized baboons. Kidney Int.78(2), 152–159 (2010).
   PubMed Web of Science ®Google Scholar
• Gesuete R, Storini C, Fantin A et al. Recombinant C1 inhibitor in brain ischemic injury. Ann. Neurol.66(3), 332–342 (2009).
   PubMed Web of Science ®Google Scholar